Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer

Detalles Bibliográficos
Autores principales: Zhang, Xuexia, Cai, Xiaoping, Zheng, Hao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Letters to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977173/
https://www.ncbi.nlm.nih.gov/pubmed/35199960
http://dx.doi.org/10.1111/1759-7714.14358
_version_ 1784680712542093312
author Zhang, Xuexia
Cai, Xiaoping
Zheng, Hao
author_facet Zhang, Xuexia
Cai, Xiaoping
Zheng, Hao
author_sort Zhang, Xuexia
collection PubMed
description
format Online
Article
Text
id pubmed-8977173
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley & Sons Australia, Ltd
record_format MEDLINE/PubMed
spelling pubmed-89771732022-04-05 Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer Zhang, Xuexia Cai, Xiaoping Zheng, Hao Thorac Cancer Letters to the Editor John Wiley & Sons Australia, Ltd 2022-02-24 2022-04 /pmc/articles/PMC8977173/ /pubmed/35199960 http://dx.doi.org/10.1111/1759-7714.14358 Text en © 2022 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Letters to the Editor
Zhang, Xuexia
Cai, Xiaoping
Zheng, Hao
Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
title Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
title_full Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
title_fullStr Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
title_full_unstemmed Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
title_short Anti‐PD1 or anti‐PD‐L1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
title_sort anti‐pd1 or anti‐pd‐l1 antibodies alone or in combination with chemotherapy first‐line treatment of advanced non‐small cell lung cancer
topic Letters to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8977173/
https://www.ncbi.nlm.nih.gov/pubmed/35199960
http://dx.doi.org/10.1111/1759-7714.14358
work_keys_str_mv AT zhangxuexia antipd1orantipdl1antibodiesaloneorincombinationwithchemotherapyfirstlinetreatmentofadvancednonsmallcelllungcancer
AT caixiaoping antipd1orantipdl1antibodiesaloneorincombinationwithchemotherapyfirstlinetreatmentofadvancednonsmallcelllungcancer
AT zhenghao antipd1orantipdl1antibodiesaloneorincombinationwithchemotherapyfirstlinetreatmentofadvancednonsmallcelllungcancer

Ejemplares similares